GSD.V TSXV
Devonian Health Group, Inc.
1W: -10.6%
1M: -18.4%
YTD: -18.4%
C$8.00 ($5.61)
-0.20 (-2.44%)
Weekly Expected Move ±12.5%
C$6
C$7
C$8
C$9
C$10
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market CapC$22.2M ($15.6M)
52W Range0.19-15
Volume7,600
Avg Volume1,096
Beta1.32
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAndré Boulet
Employees11
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2018-10-09
Websitegroupedevonian.com
360, rue des Entrepreneurs
Montmagny, QC G5V 4T1
CA
Montmagny, QC G5V 4T1
CA
About Devonian Health Group, Inc.
Devonian Health Group, Inc. is a clinical-stage pharmaceutical company. The firm is engaged in the development of drugs for a range of autoimmune and fibroinflammatory conditions, using novel therapeutic approaches to address unmet medical needs. It offers therapeutic and cosmeceutical products. Its drug candidate, Thykamine product is issued from Devonianâs SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The company was founded by Andre P. Boulet on March 27, 2015 and is headquartered in Montmagny, Canada.
Latest News
No recent news
Recent Insider Trades
No insider trades found